Company Name
Bicara Therapeutics Inc. Common Stock
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN:
US0554771032
Currency:
USD
Full Time Employees:
103
Phone:
617 468 4219
Website:
https://www.bicara.com
Fiscal Year End:
December
IPO Date:
Sep 13, 2024
Description:
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Address:
116 Huntington Avenue, Boston, MA, United States, 02116